VVT Med Closes Second Tranche of Private Placement of Units; Over $1.8M in Total Proceeds Raised

VANCOUVER, BC, Sept. 10, 2026 /CNW/ -- VVT Med Inc. (TSXV: VVTM) (the "Company" or "VVT"), a leader in minimally invasive, non-thermal and non-tumescent solutions for venous disease, is pleased to announce that, on September 10, 2026, the Company completed the second tranche ("Tranche 2") of its previously announced non-brokered private placement offering (the "Offering").

Including the first tranche of the Offering, the Company has issued a total of 7,540,414 units (each, a "Unit") at a price of $0.25 per Unit for gross proceeds of $1,885,103.50. The Offering is comprised of three tranches, with Tranche 2 issuing 3,277,760 Units at a price of $0.25 per Unit for gross proceeds of $819,440. The Company closed the first tranche of this offering on April 22, 2026 and currently intends to complete a third and final tranche on the same terms by the end of September 2026.

Each Unit consists of one common share of the Company (each, a "Common Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each whole Warrant is exercisable into one Common Share at an exercise price of $0.375 per Warrant Share for a period of 24 months from the date of issuance.

The net proceeds from the Offering will be used to support expanded U.S. and global commercialization efforts, product manufacturing to accommodate anticipated demand, working capital and general corporate purposes. The securities issued pursuant to the Offering will be subject to a four-month hold period from the date of issuance in accordance with applicable securities laws and the policies of the TSX Venture Exchange.

In connection with the closing of Tranche 2, the Company paid certain eligible finders a cash fee of up to 8% of the gross proceeds raised in respect of the Offering from subscribers introduced by such finders to the Company, for a total of $5,200. In addition, the Company issued to eligible finders such number of finder warrants (each, a "Finder Warrant") equal to 8% of the number of Units sold under the Offering to subscribers introduced by such finders to the Company, for a total of 20,800 Finder Warrants. Each Finder Warrant will entitle the holder to acquire one Common Share at an exercise price of $0.375 per share for a period of 24 months following the date of issuance.

The completion of any additional tranche of the Offering remains subject to receipt of all necessary regulatory approvals, including acceptance by the TSX Venture Exchange. There can be no assurance that any additional tranche of the Offering will be completed on the terms described, or at all.

Debt Settlement

Further to its news releases dated August 21, 2026 and September 1, 2026, the Company is pleased to announce that it has closed its previously announced debt settlement (the "Debt Settlement") with various creditors of the Company (the "Creditors").

Pursuant to the Debt Settlement, the Company entered into debt settlement agreements with the Creditors to settle an aggregate of $212,939.76 of debt owed by the Company to the Creditors by issuing an aggregate of 741,096 common shares, of which 280,000 were issued at a deemed price of CAD$0.25 per share and 461,096 were issued at a deemed price of CAD$0.31 per share

The completion of the Debt Settlement remains subject to final acceptance by the TSX Venture Exchange (the "TSXV"). All securities issued pursuant to the Debt Settlement have been issued pursuant to a prospectus exemption and are subject to a four month and one day hold period that expires on January 11, 2027.

About VVT Med Inc.

VVT is the only FDA-cleared, standalone company offering non-thermal, non-tumescent (NT-NT) varicose vein treatment technology. VVT's catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia or downtime. Addressing the widest range of vein diameters, VVT's solutions empower physicians to treat both the medical and aesthetic aspects of vein disease via a cost-efficient, simultaneous sclerosant injection and blood aspiration process. The Company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

For more information, visit www.vvtmed.com.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the completion of an additional tranche of the Offering, the use of proceeds from the Offering, and the receipt of all necessary regulatory approvals.

Forward-looking statements are based on assumptions and expectations regarding future events, including successful execution of distribution and commercialization agreements, continued physician adoption of ScleroSafe™ and V-Block™, the availability of insurance and Medicaid reimbursement, the Company's ability to expand sales efforts in the United States and internationally, access to sufficient capital, and receipt of required regulatory approvals including TSX Venture Exchange approval for the Offering and the Debt Settlement.

These statements reflect management's current views and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Risks include, but are not limited to: failure to achieve anticipated revenue or market penetration under distribution agreements; delays in or inability to expand U.S. sales efforts; changes in reimbursement policies or healthcare regulations; physician adoption may not continue as projected; operational and financial risks, including the need for additional financing; competitive pressures and technological changes in the medical device industry; the Company's ability to complete an additional tranche of the Offering on the terms described or at all; and general economic conditions and market volatility affecting the Company's securities.

Additional risks are described in detail in the Company's public filings available on www.sedarplus.ca, including the Company's most recent Management Discussion and Analysis. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking information, whether as a result of new information, events, or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE VVT MED INC.

For further information, please contact: Erez Tetro, Chief Executive Officer, VVT Med Inc., Email: [email protected]; Jeff Maser, I3 Capital, Email: [email protected], https://i3-capital.com/vvt-medical-inc